Severe Asthma and Sleep Disorders: A Severe Asthma Network Italy (SANI) Registry Analysis
Sleep disorders are a common and relevant feature among patients with severe asthma. The two diseases influence each other worsening the severity of symptoms, quality of life and overall healthcare burden. These data suggest that, treating comorbidities, including sleep disorders, might result in a better management of asthma and so a better health outcome.
Authors
- Francesco Blasi (ORCID: https://orcid.org/0000-0002-2285-9970)
- Cristina Cardini (ORCID: https://orcid.org/0000-0002-7779-9370)
- Giorgio Walter Canonica (ORCID: https://orcid.org/0000-0001-8467-2557)
- Pierluigi Paggiaro (ORCID: https://orcid.org/0000-0002-1213-2989)
- Vincenzo Bagnardi (ORCID: https://orcid.org/0000-0002-4938-3482)
- Isabella Sala (ORCID: https://orcid.org/0000-0002-4404-4537)
- Chiara Oriecuia (ORCID: https://orcid.org/0000-0002-0079-6446)
- Enrico Marco Heffler (ORCID: https://orcid.org/0000-0002-0492-5663)
- Concetta Sirena
- Sebastian Ferri (ORCID: https://orcid.org/0000-0002-1831-9672)
- Giovanni Paoletti (ORCID: https://orcid.org/0000-0003-3953-9225)
- Valentina Marzio
- Nicolò Valli (ORCID: https://orcid.org/0009-0001-8460-9977)
- Edoardo Cavaglià
Institutions
- University of Pisa (IT)
- Humanitas University (IT)
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- IRCCS Humanitas Research Hospital (IT)
- University of Milano-Bicocca (IT)
- University of Brescia (IT)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/jaa.s558611
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Sanofi
- Chiesi Farmaceutici
- European Respiratory Society
- Regeneron Pharmaceuticals
- Allergy Therapeutics
- Celltrion
- Insmed
- Grifols
- Genentech